期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 9, 期 10, 页码 877-889出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.11.106
关键词
delayed presentation; human immunodeficiency virus; immune suppression; late presenters; management; treatment response
资金
- Bristol-Myers Squibb
- Gilead Sciences
- Janssen-Cilag
- Abbott
- Data Safety and Monitoring Board
- Advisory Panels
- Merck Sharp Dohme
- Boehringer Ingelheim
- ViiV Healthcare
Late presentation of HIV is common and is associated with several adverse outcomes including an increased risk of clinical progression, blunted immune recovery on highly active antiretroviral therapy and a greater risk of drug toxicity. Late presenters may have higher rates of poor adherence, exacerbated by the same factors that contribute to their late diagnosis, such as lack of knowledge about HIV and the benefits of highly active antiretroviral therapy. We review the definitions of, risk factors for and subsequent impact of late presentation. Evidence regarding how and when to start antiretroviral therapy, and with which agents, will be discussed, as well as issues surrounding vaccination and opportunistic infection prophylaxis for individuals with a low CD4 count. Finally, strategies to increase HIV testing uptake to reduce late presentation will be summarized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据